VistaGen’s AV-101 Snags Fast Track Designation, Other Drugmakers Move Ahead with Non-Opioid Pain Treatment Programs

AV-101 is an investigational, orally bioavailable, small molecule NMDA (N-methyl-D-aspartate) receptor glycine B antagonist without psychological or sedative side effects, according to company data. In December, AV-101 was awarded the Fast Track designation for major depressive disorder. It is currently in Phase II development for that indication.